clonidine has been researched along with bupropion in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.17) | 18.7374 |
| 1990's | 2 (4.17) | 18.2507 |
| 2000's | 26 (54.17) | 29.6817 |
| 2010's | 18 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Becker, CA; Commissaris, RL; Ellis, DM; Fontana, DJ; Hill, TJ; Schefke, DM | 1 |
| Lerer, B | 1 |
| Cloutier, G; Cubeddu, LX; Grippo, R; Gross, K; Harden, TK; Knowlton, G; Lerea, L; Shakarjian, M; Stat, M; Tanner, L | 1 |
| Biederman, J; Spencer, T; Steingard, R; Wilens, T | 1 |
| Adams, DP; Covey, LS; Glassman, AH; Johnston, JA; Robinson, MD; Sullivan, MA | 1 |
| Golding, M; Hatsukami, DK; Jamerson, BD; Kotlyar, M | 1 |
| Ali, J; Halaris, A; Lindsay De Vane, C; Nasrallah, A; Piletz, JE; Zhu, H | 1 |
| Hatsukami, DK; Kotlyar, M | 1 |
| Biederman, J; Spencer, T; Wilens, T | 1 |
| Roddy, E | 1 |
| Reeves, G; Schweitzer, J | 1 |
| Jain, M; Talwar, A; Vijayan, VK | 1 |
| Banaschewski, T; Heise, CA; Himpel, S; Rothenberger, A | 1 |
| Lichtenschopf, A; Zwick, H | 1 |
| Juniper, Z; Lee, M; McRobbie, H | 1 |
| Schroeder, SA | 1 |
| Arnsten, AF; Biederman, J; Culpepper, L; Doyle, AE; Faraone, SV; Safren, SA; Spencer, TJ; Weiss, MD; Wilens, TE | 1 |
| Foulds, J; Steinberg, MB; Williams, JM; Ziedonis, DM | 1 |
| Corelli, RL; Hudmon, KS | 1 |
| Pityaratstian, N | 1 |
| Cofta-Woerpel, L; Wetter, DW; Wright, KL | 2 |
| Wilens, TE | 1 |
| Hill, A | 1 |
| Frishman, WH | 1 |
| Bau, CH; Bizarro, L; Dobler, CJ; Kortmann, GL | 1 |
| Deissenrieder, F; Groneberg, D; Kusma, B; Mache, S; Quarcoo, D; Welte, T | 1 |
| Bhat, A; Crain, D | 1 |
| Belcon, AL | 1 |
| Alexander, GC; Conti, RM; Dorsey, ER; Dusetzina, SB; Garfield, CF; Higashi, AS; Huskamp, HA; Kornfield, R; Watson, S | 1 |
| Bernabé Barrios, MJ; Rodríguez Hermosa, JL; Santamaría Rodríguez, B; Zamarro García, C | 1 |
| Aglawe, MM; Chopde, CT; Kotagale, NR; Taksande, BG; Tripathi, SJ; Umekar, MJ | 1 |
| Ebbert, JO; Elrashidi, MY | 1 |
| Adamo, N; Atkinson, LZ; Banaschewski, T; Barbui, C; Bhatti, S; Carucci, S; Cipriani, A; Coghill, D; Cortese, S; Del Giovane, C; Hayes, AJ; Mohr-Jensen, C; Purgato, M; Shokraneh, F; Simonoff, E; Steinhausen, HC; Xia, J; Zuddas, A | 1 |
| Adamo, N; Atkinson, LZ; Banaschewski, T; Barbui, C; Carucci, S; Cipriani, A; Coghill, D; Cortese, S; Del Giovane, C; Hayes, AJ; Hollis, C; Mohr-Jensen, C; Purgato, M; Shokraneh, F; Simonoff, E; Steinhausen, HC; Tessari, L; Xia, J; Zuddas, A | 1 |
| Fernandes, MF; Fuller, B; Horman, T; Leri, F; Tigert, M; Zhou, Y | 1 |
| Achenbach, C; Akanbi, MO; Bilaver, LA; Carroll, AJ; Hitsman, B; Jordan, N; McHugh, MC; Murphy, R; O'Dwyer, LC | 1 |
| Jamal, F; Mathews, M; Mathews, N; Papa-Molter, A | 1 |
24 review(s) available for clonidine and bupropion
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Alternative therapies for bipolar disorder.
Topics: Ascorbic Acid; Bipolar Disorder; Bupropion; Carbamazepine; Choline; Clonazepam; Clonidine; Clorgyline; Demeclocycline; Fenfluramine; Humans; Methylene Blue; Phosphatidylcholines; Physostigmine; Propiophenones; Propranolol; Spironolactone; Thyroxine; Tryptophan; Valproic Acid | 1985 |
Advances in non-nicotine pharmacotherapy for smoking cessation.
Topics: Antidepressive Agents; Bupropion; Buspirone; Clonidine; Humans; Moclobemide; Narcotic Antagonists; Smoking Cessation | 2000 |
Effect of nonnicotine pharmacotherapy on smoking behavior.
Topics: Amphetamines; Bupropion; Clonidine; Doxepin; Humans; Naltrexone; Nortriptyline; Selective Serotonin Reuptake Inhibitors; Smoking Cessation | 2001 |
Managing nicotine addiction.
Topics: Administration, Inhalation; Adolescent; Adult; Antidepressive Agents, Tricyclic; Bupropion; Chewing Gum; Clonidine; Drug Combinations; Female; Humans; Logistic Models; Nicotine; Nicotinic Agonists; Nortriptyline; Pregnancy; Smoking; Sympatholytics; Tobacco Use Cessation; Tobacco Use Disorder; United States; United States Agency for Healthcare Research and Quality; Women's Health | 2002 |
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Delayed-Action Preparations; Evidence-Based Medicine; Guanfacine; Humans; Methylphenidate; Propylamines | 2004 |
Bupropion and other non-nicotine pharmacotherapies.
Topics: Administration, Inhalation; Adrenergic alpha-Agonists; Antidepressive Agents, Second-Generation; Bupropion; Clonidine; Dopamine Uptake Inhibitors; Drug Interactions; Humans; Mecamylamine; Nicotine; Nicotinic Antagonists; Smoking Cessation | 2004 |
Pharmacological management of attention-deficit hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Amphetamines; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Guanfacine; Humans; Methylphenidate; Propylamines | 2004 |
Pharmacotherapy of tobacco dependence.
Topics: Adrenergic alpha-Agonists; Adult; Antidepressive Agents, Second-Generation; Bupropion; Clonidine; Female; Humans; Male; Nicotine; Nicotinic Agonists; Smoking; Smoking Cessation; Tobacco Use Disorder; United States | 2004 |
The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Adult; Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Child; Clonidine; Desipramine; Guanfacine; Humans; Imipramine; Nortriptyline; Propylamines | 2005 |
Non-nicotine pharmacotherapies for smoking cessation.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents, Tricyclic; Bupropion; Clonidine; Dopamine Uptake Inhibitors; Humans; Nortriptyline; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Smoking Prevention | 2005 |
Developments in pharmacotherapy for tobacco dependence: past, present and future.
Topics: Adolescent; Adult; Bupropion; Clinical Trials as Topic; Clonidine; Drug Administration Routes; Female; Humans; Male; Nicotine; Nicotinic Agonists; Nortriptyline; Pregnancy; Smoking Cessation; Smoking Prevention; Treatment Outcome | 2006 |
Pharmacologic interventions for smoking cessation.
Topics: Administration, Cutaneous; Administration, Inhalation; Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Chewing Gum; Clonidine; Critical Care; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Nurse's Role; Patient Education as Topic; Patient Selection; Phytotherapy; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking Cessation; Smoking Prevention; United States; United States Food and Drug Administration; Varenicline | 2006 |
Advances in alternative pharmacotherapy of ADHD.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Bupropion; Clonidine; Donepezil; Humans; Indans; Piperidines; Treatment Outcome | 2005 |
Smoking cessation 1: pharmacological treatments.
Topics: Bupropion; Clonidine; Female; Humans; Male; Nicotine; Smoking Cessation | 2006 |
Mechanism of action of agents used in attention-deficit/hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Guanfacine; Humans; Nicotinic Antagonists; Pharmacogenetics; Propylamines | 2006 |
A cost-effectiveness evaluation of single and combined smoking cessation interventions in Texas.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Bupropion; Clonidine; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Health Care Costs; Humans; Nicotine; Nortriptyline; Smoking; Smoking Cessation; Texas; Tobacco Use Disorder; Treatment Outcome | 2006 |
Smoking cessation 3: multicomponent interventions.
Topics: Behavior Therapy; Bupropion; Clonidine; Combined Modality Therapy; Humans; Motivation; Nicotine; Nortriptyline; Psychotherapy, Brief; Smoking Cessation; Tobacco Use Disorder | 2007 |
Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations.
Topics: Administration, Cutaneous; Administration, Inhalation; Benzazepines; Bupropion; Chewing Gum; Clonidine; Coronary Artery Disease; Humans; Monoamine Oxidase Inhibitors; Nicotine; Nortriptyline; Piperidines; Pyrazoles; Quinoxalines; Receptors, Nicotinic; Rimonabant; Selective Serotonin Reuptake Inhibitors; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Tobacco, Smokeless; Varenicline | 2007 |
Pharmacogenetics of smoking cessation therapy.
Topics: Benzazepines; Bupropion; Clonidine; Genome-Wide Association Study; Humans; Nicotine; Nortriptyline; Pharmacogenetics; Quinoxalines; Smoking Cessation; Varenicline | 2010 |
[Smoking in COPD].
Topics: Benzazepines; Bupropion; Clonidine; Comorbidity; Disease Progression; Europe; Humans; Motivation; Nicotinic Agonists; Nortriptyline; Prevalence; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Severity of Illness Index; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Varenicline | 2011 |
Emerging drugs for the treatment of tobacco dependence: 2014 update.
Topics: Atomoxetine Hydrochloride; Benzazepines; Bupropion; Clinical Trials as Topic; Clonidine; Humans; Mecamylamine; Nicotine; Nortriptyline; Propylamines; Quinoxalines; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2014 |
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Dose-Response Relationship, Drug; Humans; Methylphenidate; Network Meta-Analysis; Randomized Controlled Trials as Topic | 2018 |
The efficacy of smoking cessation interventions in low- and middle-income countries: a systematic review and meta-analysis.
Topics: Adult; Behavior Therapy; Bupropion; Cigarette Smoking; Clonidine; Counseling; Developing Countries; Humans; Mobile Applications; Naltrexone; Nortriptyline; Randomized Controlled Trials as Topic; Smoking Cessation; Smoking Cessation Agents; Tobacco Use Cessation Devices; Varenicline | 2019 |
2 trial(s) available for clonidine and bupropion
| Article | Year |
|---|---|
Bupropion does not antagonize cardiovascular actions of clonidine in normal subjects and spontaneously hypertensive rats.
Topics: Adult; Animals; Blood Platelets; Blood Pressure; Bupropion; Clonidine; Desipramine; Heart Rate; Humans; Imipramine; In Vitro Techniques; Male; Propiophenones; Rats; Rats, Inbred Strains; Tritium; Yohimbine | 1984 |
Down-regulation of platelet imidazoline-1-binding sites after bupropion treatment.
Topics: Antidepressive Agents, Second-Generation; Binding Sites; Blood Platelets; Bupropion; Clonidine; Depressive Disorder; Dose-Response Relationship, Drug; Down-Regulation; Humans; Imidazoline Receptors; Psychiatric Status Rating Scales; Receptors, Drug; Time Factors | 2002 |
22 other study(ies) available for clonidine and bupropion
| Article | Year |
|---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Chronic antidepressant and clonidine treatment effects on conflict behavior in the rat.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Clonidine; Conflict, Psychological; Desipramine; Female; Mianserin; Panic; Propiophenones; Rats; Rats, Inbred Strains; Time Factors; Trazodone | 1990 |
Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette's syndrome.
Topics: Attention Deficit Disorder with Hyperactivity; Bupropion; Child; Clonidine; Desipramine; Female; Humans; Male; Nortriptyline; Tourette Syndrome; Treatment Outcome | 1993 |
[Smoking, nicotine dependence and detoxification therapies].
Topics: Administration, Cutaneous; Administration, Intranasal; Adrenergic alpha-Agonists; Antidepressive Agents; Bupropion; Chewing Gum; Clonidine; Dopamine Uptake Inhibitors; Health Promotion; Humans; Nicotine; Smoking; Smoking Cessation; Tobacco Use Disorder | 2002 |
[COPD-rehabilitation].
Topics: Acupuncture Therapy; Adrenergic alpha-Agonists; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Aversive Therapy; Body Weight; Bupropion; Clinical Trials as Topic; Clonidine; Exercise; Humans; Hypnosis; Nortriptyline; Patient Education as Topic; Physical Endurance; Pulmonary Disease, Chronic Obstructive; Respiratory Muscles; Smoking Cessation | 2005 |
What to do with a patient who smokes.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Stimulants; Clonidine; Counseling; Hotlines; Humans; Nicotine; Nortriptyline; Physician's Role; Smoking; Smoking Cessation; Tobacco Use Disorder; United States | 2005 |
New developments in the treatment of ADHD.
Topics: Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Cognitive Behavioral Therapy; Guanfacine; Humans; Modafinil; Nicotinic Agonists; Physician's Role; Primary Health Care; Propylamines; Treatment Outcome | 2006 |
[Current and future medical drugs for smoking cessation].
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Clonidine; Combined Modality Therapy; Counseling; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking Cessation; Tobacco Use Disorder; Vaccines; Varenicline | 2009 |
Current treatment options in smoking cessation.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Clonidine; Combined Modality Therapy; Counseling; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Patient Selection; Piperidines; Practice Guidelines as Topic; Pyrazoles; Quinoxalines; Rimonabant; Self-Help Groups; Smoking Cessation; Tobacco Use Disorder; United States; Vaccines; Varenicline | 2010 |
Smoking cessation pharmacotherapy: a concise overview.
Topics: Adrenergic alpha-2 Receptor Agonists; Antidepressive Agents; Benzazepines; Bupropion; Clonidine; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2011 |
Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Dopamine Uptake Inhibitors; Drug Utilization; Guanfacine; Humans; Practice Patterns, Physicians'; Propylamines; United States; United States Food and Drug Administration | 2013 |
Evidences for the agmatine involvement in antidepressant like effect of bupropion in mouse forced swim test.
Topics: Agmatine; Animals; Antidepressive Agents; Arginine; Benzofurans; Biguanides; Bupropion; Clonidine; Dose-Response Relationship, Drug; Drug Interactions; Eflornithine; Guanidines; Idazoxan; Imidazoles; Immobility Response, Tonic; Injections, Intraventricular; Male; Mice; Motor Activity | 2013 |
Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Clinical Protocols; Clonidine; Dose-Response Relationship, Drug; Humans; Methylphenidate; Network Meta-Analysis; Treatment Outcome | 2017 |
An exploration of the aversive properties of 2-deoxy-D-glucose in rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Analysis of Variance; Animals; Behavior, Animal; Blood Glucose; Bupropion; Clonidine; Corticosterone; Deoxyglucose; Disease Models, Animal; Dopamine Uptake Inhibitors; Hypoglycemia; Locomotion; Male; Norepinephrine; Rats; Rats, Sprague-Dawley | 2018 |
Bupropion-Induced Nightmares Treated With Clonidine.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Bupropion; Clonidine; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Dreams; Female; Humans; Sleep, REM | 2019 |